MDCT of primary, locally recurrent, and metastatic duodenal gastrointestinal stromal tumours (GISTs): A single institution study of 25 patients with review of literature

2014 ◽  
Vol 69 (2) ◽  
pp. 137-144 ◽  
Author(s):  
J.M. Cheng ◽  
S.H. Tirumani ◽  
A.B. Shinagare ◽  
J.P. Jagannathan ◽  
J.L. Hornick ◽  
...  
2013 ◽  
Vol 31 (1) ◽  
Author(s):  
Corey Beals ◽  
Alan Rogers ◽  
Paul Wakely ◽  
Joel L. Mayerson ◽  
Thomas J. Scharschmidt

Oncotarget ◽  
2017 ◽  
Vol 9 (10) ◽  
pp. 8801-8809 ◽  
Author(s):  
Aman Chauhan ◽  
Millicent Horn ◽  
Gray Magee ◽  
Kurt Hodges ◽  
Mark Evers ◽  
...  

Neurosurgery ◽  
2012 ◽  
Vol 72 (3) ◽  
pp. 332-340 ◽  
Author(s):  
Jamie J. Van Gompel ◽  
Matthew L. Carlson ◽  
Bruce E. Pollock ◽  
Eric J. Moore ◽  
Robert L. Foote ◽  
...  

Abstract BACKGROUND: Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine tumor considered to be radiation sensitive. Local recurrence may be treated in a variety of ways, including stereotactic radiosurgery (SRS); however, little information on its effectiveness is available. OBJECTIVE: To determine whether SRS is effective in providing local control for recurrent ENB. METHODS: This was a retrospective single-institution experience including 109 patients with ENB treated at the Mayo Clinic (1962–2009). Sixty-three patients presented with Kadish stage C disease, and 21 patients developed local recurrence. Of these 21 patients, 7 patients underwent SRS at our institution and an additional patient underwent SRS after transnasal biopsy. Therefore, a total of 8 patients are reported. RESULTS: The median age at time of local recurrence was 50 years. All patients had Kadish C disease at initial diagnosis. Six of 8 patients were found to have Hyams grade 3 disease; the remaining 2 patients had grade 2 disease. The median treatment volume was 8.4 cm3 (mean, 18.9 cm3; range, 1.4-76.3 cm3), and the median dose to the tumor margin was 15 Gy (mean, 14.4 ± 2.2 Gy; range, 10-18 Gy). Of the 16 treatments, 13 had adequate follow-up to assess treatment response, with 92% achieving local control over a median follow-up of 42 months from the time of SRS. Five lesions decreased in size, 7 lesions stabilized, and only 1 lesion had in-field progression. There were no documented complications secondary to SRS. CONCLUSION: SRS appears to be a reasonable and safe option for treatment of intracranial recurrence of ENB.


2010 ◽  
Vol 29 (2) ◽  
pp. 100-106 ◽  
Author(s):  
Munira Shabbir ◽  
John Lucas ◽  
John Lazarchick ◽  
Keisuke Shirai

Sign in / Sign up

Export Citation Format

Share Document